![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ESP Pharma Acquires Exclusive North American Rights to Retavase
ESP Pharma Acquires Exclusive North American Rights to Retavase
ESP Pharma, a niche pharmaceutical company focused on the acquisition, marketing and late-stage development of life-saving acute-care therapeutics, has announced the acquisition, by ESP Pharma, of U.S. and Canadian rights to Retavase (reteplase) from Centocor, a biopharmaceutical operating company of Johnson & Johnson. Scios, another Johnson & Johnson company, currently markets the product on behalf of Centocor.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct